Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
chelation agent |
| gptkbp:administeredBy |
intramuscular injection
subcutaneous injection intravenous injection |
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:V03AC01
|
| gptkbp:brand |
gptkb:Desferal
|
| gptkbp:CASNumber |
70-51-9
|
| gptkbp:category |
antidote
World Health Organization essential medicine iron chelator |
| gptkbp:chemicalFormula |
C25H48N6O8
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to desferrioxamine |
| gptkbp:discoveredBy |
Hans Theil
|
| gptkbp:elimination_route |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
Desferrioxamine
|
| gptkbp:KEGGID |
D00110
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds free iron
forms ferrioxamine complex |
| gptkbp:molecularWeight |
560.684 g/mol
|
| gptkbp:origin |
produced by Streptomyces pilosus
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
2973
2868 CHEMBL1200697 DB00552 |
| gptkbp:routeOfAdministration |
parenteral
|
| gptkbp:sideEffect |
vision problems
hearing loss allergic reactions growth retardation lung problems |
| gptkbp:UNII |
J06Y7MXW4D
|
| gptkbp:usedFor |
gptkb:thalassemia_major
treatment of aluminum toxicity sideroblastic anemia acute iron poisoning transfusional hemosiderosis treatment of iron overload |
| gptkbp:bfsParent |
gptkb:Deferoxamine
|
| gptkbp:bfsLayer |
6
|